OncoSec moves exec staff from San Diego to Pennington
Merck and OncoSec expand Keytruda/IL-12 collaboration into triple-negative breast cancer
OncoSec looks to boost effects of immunotherapy with intratumoral delivery
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
Melanoma: Intratumoral Injection Converts Cold Tumors to Hot
Will tiny OncoSec break out with promising melanoma immunotherapy study results?
OncoSec shares turn hot as microcap reports promising PhII data for an I/O one-two punch
3 Ways the Lean Startup Approach Is Revolutionizing Healthcare
OncoSec LIVE from the New York Stock Exchange Floor
Improving Anti-PD-1 Response Rate: The Potential Role of a Combination Therapy
Intratumoral Therapy Increases Response to Checkpoint Inhibitor for Melanoma
How Technology Will Shape the Future of Cancer Treatments.
Op-Ed: I Have Terminal Cancer.
Cancer Immunotherapy has Life-Saving Powers – and Limits
These Startups Are Disrupting the Healthcare Industry With Targeted Cancer Treatments. Read the full story
Immunotherapy Inside the Cell: Three Companies on Their Way to the ‘Holy Grail’ of Cancer Treatment. Read the full story
OncoSec Advances ‘Smart’ Electroporation Technology For Minimally Invasive Immunotherapy. Read the full story
Cancer immunotherapy is providing options for patients who are out of options. Read the interview